How many clinical trials are tracked for SARS-CoV-2 infection?

106 trials are tracked, 34 with published results.

SARS-CoV-2 infection Research

SARS-CoV-2 infection: what the trials found

Several vaccines have demonstrated immunogenicity and safety in diverse populations. [NEW] BNT162b2 (original and bivalent formulations) and mRNA-1273 (including variant-adapted versions) elicited robust neutralizing antibody responses and seroresponse rates, with acceptable reactogenicity profiles ¹²⁵⁸¹¹¹²¹³¹⁴²⁰²². For example, mRNA-1273.211 showed geometric mean fold rises against XBB.1.5, BA.4/BA.5, and BQ.1.1 ¹¹, and BNT162b2 bivalent (original/Omicron BA.4/BA.5) had no grade ≥3 laboratory shifts ⁵. NVX-Cov2373 and Novavax COVID-19 vaccine (2023-2024 formula) were also studied ³⁹. CVnCoV reduced virologically-confirmed COVID-19 cases (p=0.016) ¹⁵.

In therapeutic interventions, tocilizumab did not significantly reduce mechanical ventilation or death (p=0.64) or clinical worsening (p=0.73) ¹⁰. CT-P59 reduced hospitalization, oxygen therapy, or mortality in high-risk patients (p<0.0001) ¹⁶. Hydroxychloroquine sulfate was evaluated ¹⁷. ACE inhibitors/angiotensin receptor blockers showed no significant difference in SOFA score or blood pressure outcomes ⁷. Dornase alfa inhalation solution and hyperimmune immunoglobulin (hIVIG) were studied but without significant efficacy signals ¹⁸¹⁹. TXA127 did not improve oxygen-free days or hospital-free days ²¹.

Safety data from large trials indicate that local and systemic reactions were generally mild to moderate. For BNT162b2, local reactions occurred in up to 7.6% after dose 1 and 6.0% after dose 2 ⁸; systemic events were reported in up to 11.8% after dose 1 ⁸. In a phase 3 trial, adverse events occurred in 26.3% of BNT162b2 recipients ¹³. mRNA-1273.529 had solicited reactogenicity in 84.5-89.9% of participants ²⁰. No unexpected safety concerns were identified.

For the clinician treating this condition

BNT162b2 and mRNA-1273 vaccines (including variant-adapted versions) are immunogenic with acceptable safety profiles.
CT-P59 reduced hospitalization and mortality in high-risk patients; tocilizumab and hydroxychloroquine did not show benefit.
No therapeutic intervention (ACE inhibitors, dornase alfa, hIVIG, TXA127) demonstrated clear efficacy in hospitalized patients.

AI synthesis of 22 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

SARS-CoV-2 infection: current evidence & treatments

SARS-CoV-2 infection interacts with host E3 ubiquitin ligases to modulate viral replication and immune evasion, including inhibition of interferon production ¹. The virus can also induce intestinal dysbiosis and modify immune signaling, with potential effects on neuropsychiatric and metabolic complications via the microbiota-gut-brain axis ¹¹. Mechanistically, SARS-CoV-2 relies on ACE2 receptors and TMPRSS2-mediated membrane fusion, hijacks the endoplasmic reticulum to induce stress responses, and can be detected as particles measuring 70-100 nm in infected cell supernatants [18, 24].

Post-acute sequelae of COVID-19 include significant thromboembolic risk ², a 41% increased risk of new-onset diabetes ¹³, and cardiovascular manifestations that require mechanism-informed, subgroup-based management ⁷. Omicron variants are associated with increased prevalence of multisystem long COVID and gastrointestinal symptoms ²⁵. In children, two doses of SARS-CoV-2 vaccine show a protective effect against multisystem inflammatory syndrome (MIS-C) ¹⁴. For acute treatment, casirivimab plus imdevimab reduced risk of hospitalization or death in outpatients ³, while convalescent plasma did not reduce mortality in moderate to severe disease ¹⁵. Interleukin-7 therapy improved lymphocyte counts but did not reduce mortality in sepsis or COVID-19 ⁸.

Safety and pharmacokinetic data show that nirmatrelvir/ritonavir in breast milk results in low infant exposure (1.8% of maternal dose for nirmatrelvir) ²¹, and intramuscular adintrevimab for prophylaxis had a 2.0% incidence of systemic treatment-emergent adverse events within 7 days ¹⁹. Clozapine use in severe mental disorders is linked to higher SARS-CoV-2 infection risk ²². Inactivated SARS-CoV-2 vaccines (CoronaVac and Covilo) in adults aged 60-80 years induced neutralizing antibody geometric mean titers up to 59.4 under certain dosing schedules ²³. High COVID-19 immunization coverage (93.2%) was achieved in Ghana ¹⁰, and a semantic FAIRness framework has been proposed to enhance COVID-19 data integration in the UAE ⁴.

SARS-CoV-2 modulates host E3 ubiquitin ligases to evade immune responses and promote replication ¹.

Post-COVID syndrome carries significant thromboembolic risk ² and a 41% increased risk of new-onset diabetes ¹³.

Two doses of SARS-CoV-2 vaccine protect against MIS-C in children ¹⁴.

Casirivimab plus imdevimab reduces hospitalization or death in outpatients ³, while convalescent plasma does not reduce mortality ¹⁵.

Nirmatrelvir/ritonavir in breast milk results in low infant exposure ²¹.